Methods to manufacture regulatory T cells for cell therapy

Regulatory T cell (Treg) therapy has shown promise in early clinical trials for treating graft‐versus‐host disease, transplant rejection and autoimmune disorders. A challenge has been to isolate sufficiently pure Tregs and expand them to a clinical dose. However, there has been considerable progress in the development and optimization of these methods, resulting in a variety of manufacturing protocols being tested in clinical trials. In this review, we summarize methods that have been used to manufacture Tregs for clinical trials, including the choice of cell source and protocols for cell isolation and expansion. We also discuss alternative culture or genome editing methods for modulating Treg specificity, function or stability that could be applied to future clinical manufacturing protocols to increase the efficacy of Treg therapy.

• Publication year

  2019

• Venue

  Clinical and Experimental Immunology

• Publication date

  2019-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/cei.13297PMID 30913302PMCID PMC6591148
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• mTOR Inhibitor Everolimus in Regulatory T Cell Expansion for Clinical Application in Transplantation

  2019cited by this paper
• Genetic Engineering of T Cells for Immune Tolerance

  2019cited by this paper
• CD4+FOXP3+ Regulatory T Cell Therapies in HLA Haploidentical Hematopoietic Transplantation

  2019cited by this paper
• Regulatory T cells: exploring mechanisms for future therapies

  2019cited by this paper
• Adoptive Treg Cell Therapy in a Patient With Systemic Lupus Erythematosus

  2019cited by this paper
• A Rapamycin-Based GMP-Compatible Process for the Isolation and Expansion of Regulatory T Cells for Clinical Trials

  2018cited by this paper
• First-in-Human Clinical Trial to Determine the Safety and Potency of Inducible T Regulatory Cells after Allogeneic Hematopoietic Cell Transplantation

  2018cited by this paper
• Conversion of T-Effector Cells to Immunosuppressive T-Regulatory-like Cells By CRISPR/Cas9-Mediated Integration of a FOXP3 Transgene

  2018cited by this paper
• Industrializing Autologous Adoptive Immunotherapies: Manufacturing Advances and Challenges

  2018cited by this paper
• Clinical Grade Regulatory CD4+ T Cells (Tregs): Moving Toward Cellular-Based Immunomodulatory Therapies

  2018cited by this paper
• Cell banking for regulatory T cell-based therapy: strategies to overcome the impact of cryopreservation on the Treg viability and phenotype

  2018cited by this paper
• Tailoring the homing capacity of human Tregs for directed migration to sites of Th1‐inflammation or intestinal regions

  2018cited by this paper
• Functional Interrogation of Primary Human T Cells via CRISPR Genetic Editing

  2018cited by this paper
• Toward precision manufacturing of immunogene T-cell therapies.

  2018cited by this paper
• An optimized method to measure human FOXP3+ regulatory T cells from multiple tissue types using mass cytometry

  2018cited by this paper
• Engineering therapeutic T cells to suppress alloimmune responses using TCRs, CARs, or BARs

  2018cited by this paper
• A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T cells in Living Donor Kidney Transplants

  2018cited by this paper
• Producing proT cells to promote immunotherapies

  2018cited by this paper
• Expanded autologous regulatory T-lymphocyte infusions in ALS

  2018cited by this paper
• Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials.

  2017cited by this paper
• Cell-Based Therapies with T Regulatory Cells

  2017cited by this paper
• Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection

  2017cited by this paper
• Forkhead-Box-P3 Gene Transfer in Human CD4+ T Conventional Cells for the Generation of Stable and Efficient Regulatory T Cells, Suitable for Immune Modulatory Therapy

  2017cited by this paper
• Mild hypothermia provides Treg stability

  2017cited by this paper
• Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.

  2017cited by this paper
• Polyclonal Regulatory T Cell Therapy for Control of Inflammation in Kidney Transplants

  2017cited by this paper
• Engineered Tolerance: Tailoring Development, Function, and Antigen-Specificity of Regulatory T Cells

  2017cited by this paper
• Prevention of Allograft Rejection by Use of Regulatory T Cells With an MHC‐Specific Chimeric Antigen Receptor

  2017cited by this paper
• HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells

  2017cited by this paper
• Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

  2017cited by this paper
• Harnessing Advances in T Regulatory Cell Biology for Cellular Therapy in Transplantation

  2017cited by this paper
• Antigen-specific regulatory T cells: are police CARs the answer?

  2017cited by this paper
• In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines

  2017cited by this paper
• Stem cell-derived tissue-associated regulatory T cells ameliorate the development of autoimmunity

  2016cited by this paper
• Discarded Human Thymus Is a Novel Source of Stable and Long‐Lived Therapeutic Regulatory T Cells

  2016cited by this paper
• Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor.

  2016cited by this paper
• CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

  2016cited by this paper
• Engineered T cells: the promise and challenges of cancer immunotherapy

  2016cited by this paper
• A Phase I Study of Donor Regulatory T Cells As Treatment for Steroid Dependent/Refractory Chronic Graft Versus Host Disease

  2016cited by this paper
• Expansion of Human Tregs from Cryopreserved Umbilical Cord Blood for GMP-Compliant Autologous Adoptive Cell Transfer Therapy

  2016cited by this paper
• A robust, good manufacturing practice-compliant, clinical-scale procedure to generate regulatory T cells from patients with amyotrophic lateral sclerosis for adoptive cell therapy.

  2016cited by this paper
• Successful expansion of functional and stable regulatory T cells for immunotherapy in liver transplantation

  2016cited by this paper
• Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect.

  2016cited by this paper
• Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors.

  2016cited by this paper
• Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo.

  2015cited by this paper
• Type 1 diabetes immunotherapy using polyclonal regulatory T cells

  2015cited by this paper
• Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies.

  2015cited by this paper
• Hypoxic culture conditions enhance the generation of regulatory T cells

  2015cited by this paper
• Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement

  2015cited by this paper
• Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease

  2015cited by this paper
• Control of tissue‐localized immune responses by human regulatory T cells

  2015cited by this paper
• Sequential Monitoring and Stability of Ex Vivo–Expanded Autologous and Nonautologous Regulatory T Cells Following Infusion in Nonhuman Primates

  2015cited by this paper
• Glutamine-dependent α-ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation

  2015cited by this paper
• Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease.

  2015cited by this paper
• Hurdles in therapy with regulatory T cells

  2015cited by this paper
• Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease

  2015cited by this paper
• Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up.

  2014cited by this paper
• HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse.

  2014cited by this paper
• Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease.

  2014cited by this paper
• Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells.

  2014cited by this paper
• The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic Treg Cell Homeostasis

  2013cited by this paper
• Toward eliminating HLA class I expression to generate universal cells from allogeneic donors.

  2013cited by this paper
• Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells

  2013cited by this paper
• Metabolites produced by commensal bacteria promote peripheral regulatory T cell generation

  2013cited by this paper
• Clinical Grade Manufacturing of Human Alloantigen‐Reactive Regulatory T Cells for Use in Transplantation

  2013cited by this paper
• Homing of Regulatory T Cells to Human Skin Is Important for the Prevention of Alloimmune-Mediated Pathology in an In Vivo Cellular Therapy Model

  2012cited by this paper
• CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery

  2012cited by this paper
• Administration of CD4+CD25highCD127− Regulatory T Cells Preserves β-Cell Function in Type 1 Diabetes in Children

  2012cited by this paper
• The battle against immunopathology: infectious tolerance mediated by regulatory T cells

  2012cited by this paper
• Cryopreservation modulates the detection of regulatory T cell markers

  2012cited by this paper
• Regulatory T-cell therapy for transplantation: how many cells do we need?

  2012cited by this paper
• Peak serum: implications of serum supply for cell therapy manufacturing.

  2012cited by this paper
• This information is current as Autoimmunity Pluripotent Stem Cells and Prevention of Programming of Regulatory T Cells from Bian

  2012cited by this paper
• Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation.

  2011cited by this paper
• Regulation of HLA class II expression prevents allogeneic T-cell responses.

  2011cited by this paper
• T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

  2011cited by this paper
• Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1.

  2011cited by this paper
• Massive ex Vivo Expansion of Human Natural Regulatory T Cells (Tregs) with Minimal Loss of in Vivo Functional Activity

  2011cited by this paper
• Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.

  2011cited by this paper
• Accelerated Production of Antigen-specific T Cells for Preclinical and Clinical Applications Using Gas-permeable Rapid Expansion Cultureware (G-Rex)

  2010cited by this paper
• Cryopreservation does not alter the frequency of regulatory T cells in peripheral blood mononuclear cells.

  2010cited by this paper
• Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response.

  2009cited by this paper
• First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells.

  2009cited by this paper
• Human T regulatory cell therapy: take a billion or so and call me in the morning.

  2009cited by this paper
• Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy

  2009cited by this paper
• Differential Responses of Human Regulatory T Cells (Treg) and Effector T Cells to Rapamycin

  2009cited by this paper
• Frequency of human T regulatory cells in peripheral blood is significantly reduced by cryopreservation.

  2009cited by this paper
• Effects of cryopreservation on CD4+ CD25+ T cells of HIV‐1 infected individuals

  2008cited by this paper
• Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice.

  2008cited by this paper
• Inducible reprogramming of human T cells into Treg cells by a conditionally active form of FOXP3

  2008cited by this paper
• Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells.

  2008cited by this paper
• Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3.

  2008cited by this paper
• Clinical Grade Treg: GMP Isolation, Improvement of Purity by CD127pos Depletion, Treg Expansion, and Treg Cryopreservation

  2008cited by this paper
• Comparative Study of Regulatory T Cell Function of Human CD25+CD4+ T Cells from Thymocytes, Cord Blood, and Adult Peripheral Blood

  2008cited by this paper
• Hypoxia controls CD4+CD25+ regulatory T‐cell homeostasis via hypoxia‐inducible factor‐1α

  2008cited by this paper
• Tolerance induction by third-party "off-the-shelf" CD4+CD25+ Treg cells.

  2006cited by this paper
• Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion.

  2006cited by this paper
• CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells

  2006cited by this paper
• CD25+CD4+ T cells in human cord blood: an immunoregulatory subset with naive phenotype and specific expression of forkhead box p3 (Foxp3) gene.

  2004cited by this paper
• L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection.

  2004cited by this paper

• Metabolic reprogramming of naïve regulatory T cells by IL-7 and IL-15 promotes their persistence and performance upon adoptive transfer

  2025cites this paper
• Regulatory T cell therapy in solid organ transplantation: clinical applications and laboratory monitoring strategies

  2025cites this paper
• Navigating the manufacturing, testing and regulatory complexities of regulatory T cells for adoptive cell therapy

  2025cites this paper
• Unlocking the therapeutic potential of thymus-isolated regulatory T cells

  2025cites this paper
• CD4+CD25+ regulatory T cell therapy in neurological autoimmune diseases

  2025cites this paper
• Clinical grade expansion protocol for the manufacture of thymus-derived Treg cells for clinical application

  2025cites this paper
• Expression of an interleukin-2 partial agonist enhances regulatory T cell persistence and efficacy in mouse autoimmune models

  2025cites this paper
• Treg cell therapy manufacturability: current state of the art, challenges and new opportunities

  2025influential citation
• Regulatory T cell-based therapies for type 1 diabetes: a narrative review

  2025cites this paper
• Long noncoding RNA BCYRN1 promotes cardioprotection by enhancing human and murine regulatory T cell dynamics

  2025cites this paper
• Forkhead Box Protein P3 in the Immune System

  2025cites this paper
• Advanced-Therapy Medicinal Products: Challenges for Implementation in Pediatric Clinical Practice

  2024cites this paper
• Experience in manufacturing a haploidentical biomedical cell product enriched with regulatory T-lymphocytes

  2024cites this paper
• A phase 2 randomized trial with autologous polyclonal expanded regulatory T cells in children with new-onset type 1 diabetes

  2024cites this paper
• Clinical grade multiparametric cell sorting and gene-marking of regulatory T cells.

  2024cites this paper
• The CD4 T cell epigenetic JUNB+ state is associated with proliferation and exhaustion

  2024cites this paper
• Clinical Manufacturing of Regulatory T Cell Products For Adoptive Cell Therapy and Strategies to Improve Therapeutic Efficacy

  2023influential citation
• Promises and Pitfalls of Next-Generation Treg Adoptive Immunotherapy

  2023cites this paper
• Role of the immune system in liver transplantation and its implications for therapeutic interventions

  2023cites this paper
• Modulatory immune responses in fungal infection associated with organ transplant - advancements, management, and challenges

  2023cites this paper
• Human CD4+CD25+ T cells expressing a chimeric antigen receptor against aberrant superoxide dismutase 1 trigger antigen-specific immunomodulation.

  2023cites this paper
• First-in-human therapy with Treg produced from thymic tissue (thyTreg) in a heart transplant infant

  2023cites this paper
• 100 years post-insulin: immunotherapy as the next frontier in type 1 diabetes

  2023cites this paper
• Combining Treg Therapy With Donor Bone Marrow Transplantation: Experimental Progress and Clinical Perspective

  2023cites this paper
• IL-7 improves the fitness of regulatory T cells for adoptive transfer

  2023cites this paper
• Interleukin‐7 improves the fitness of regulatory T cells for adoptive transfer

  2023cites this paper
• Umbilical cord blood and peripheral blood-derived regulatory T cells therapy: Progress in type 1 diabetes.

  2023cites this paper
• Donor antigen-specific regulatory T cell administration to recipients of live donor kidneys: A ONE Study consortium pilot trial.

  2023cites this paper
• Bioengineered particles expand myelin-specific regulatory T cells and reverse autoreactivity in a mouse model of multiple sclerosis

  2023cites this paper
• Regulatory T cell dysfunction and its implication for cell therapy.

  2023cites this paper
• Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion

  2023cites this paper
• Engineered Treg cells: The heir to the throne of immunotherapy.

  2023cites this paper
• Flagellin-specific human CAR Tregs for immune regulation in IBD.

  2022cites this paper
• Emerging strategies for treating autoimmune disorders with genetically modified Treg cells.

  2022cites this paper
• Engineered T cells and their therapeutic applications in autoimmune diseases

  2022cites this paper
• Engineering of regulatory T cells by means of mRNA electroporation in a GMP-compliant manner.

  2022cites this paper
• PTEN is required for human Treg suppression of costimulation

  2022cites this paper
• Modeling the Potential of Treg-Based Therapies for Transplant Rejection: Effect of Dose, Timing, and Accumulation Site

  2022cites this paper
• A Novel GMP Protocol to Produce High-Quality Treg Cells From the Pediatric Thymic Tissue to Be Employed as Cellular Therapy

  2022cites this paper
• Tregs in Autoimmunity: Insights Into Intrinsic Brake Mechanism Driving Pathogenesis and Immune Homeostasis

  2022cites this paper
• Emerging translational strategies and challenges for enhancing regulatory T cell therapy for graft-versus-host disease

  2022cites this paper
• Regulatory T Cells: Liquid and Living Precision Medicine for the Future of VCA

  2022cites this paper
• Do Treg Speed Up with CARs? Chimeric Antigen Receptor Treg Engineered to Induce Transplant Tolerance

  2022cites this paper
• PHLPP Signaling in Immune Cells.

  2022cites this paper
• Manufacturing next-generation regulatory T-cell therapies.

  2022cites this paper
• Cell-based therapy in prophylaxis and treatment of chronic graft-versus-host disease

  2022cites this paper
• Modelling Graft-Versus-Host Disease in Mice Using Human Peripheral Blood Mononuclear Cells.

  2022cites this paper
• The emerging role of regulatory cell-based therapy in autoimmune disease

  2022cites this paper
• Clinical and Basic Research Progress on Treg-Induced Immune Tolerance in Liver Transplantation

  2021cites this paper
• Strategies for Liver Transplantation Tolerance

  2021cites this paper
• Thymic origins of autoimmunity—lessons from inborn errors of immunity

  2021cites this paper
• 100 years post-insulin: immunotherapy as the next frontier in type 1 diabetes

  2021cites this paper
• Interleukin-5 (IL-5) Therapy Prevents Allograft Rejection by Promoting CD4+CD25+ Ts2 Regulatory Cells That Are Antigen-Specific and Express IL-5 Receptor

  2021cites this paper
• Towards tolerance in liver transplantation.

  2021cites this paper
• Polyclonal Regulatory T Cell Manufacturing Under cGMP: A Decade of Experience

  2021cites this paper
• Strong Expansion of Human Regulatory T Cells for Adoptive Cell Therapy Results in Epigenetic Changes Which May Impact Their Survival and Function

  2021cites this paper
• Antigen Specific Regulatory T Cells in Kidney Transplantation and Other Tolerance Settings

  2021cites this paper
• Pre-clinical development and molecular characterization of an engineered type 1 regulatory T-cell product suitable for immunotherapy.

  2021cites this paper
• Made to Measure: Patient-Tailored Treatment of Multiple Sclerosis Using Cell-Based Therapies

  2021cites this paper
• Mesenchymal stromal cell mitochondrial transfer to human induced T-regulatory cells mediates FOXP3 stability

  2021cites this paper
• Process development and validation of expanded regulatory T cells for prospective applications: an example of manufacturing a personalized advanced therapy medicinal product

  2021cites this paper
• Regulatory T Cell Therapy of Graft-versus-Host Disease: Advances and Challenges

  2021cites this paper
• Highly Purified Alloantigen-Specific Tregs From Healthy and Chronic Kidney Disease Patients Can Be Long-Term Expanded, Maintaining a Suppressive Phenotype and Function in the Presence of Inflammatory Cytokines

  2021influential citation
• Immune and Genome Engineering as the Future of Transplantable Tissue.

  2021cites this paper
• TGF-β1-Licensed Murine MSCs Show Superior Therapeutic Efficacy in Modulating Corneal Allograft Immune Rejection In Vivo

  2020cites this paper
• Molecular markers of regulatory T cells and their importance in anticancer chemotherapy - A comprehensive review.

  2020cites this paper
• Directed differentiation of regulatory T cells from naive T cells and prevention of their inflammation‐mediated instability using small molecules

  2020cites this paper
• Ex vivo expansion of regulatory T cells from long-term Belatacept-treated kidney transplant patients restores their phenotype and suppressive function but not their FOXP3 TSDR demethylation status.

  2020cites this paper
• Toward an Optimized Process for Clinical Manufacturing of CAR-Treg Cell Therapy.

  2020cites this paper
• From bench to patient and back - an interdisciplinary mixed-method patient-integrated approach to developing a new potential therapy for inflammatory bowel disease

  2020cites this paper
• Cross talk between human regulatory T cells and antigen‐presenting cells: Lessons for clinical applications

  2020cites this paper
• Augmented Expansion of Treg Cells From Healthy and Autoimmune Subjects via Adult Progenitor Cell Co-Culture

  2020cites this paper
• Progress in Translational Regulatory T Cell Therapies for Type 1 Diabetes and Islet Transplantation.

  2020cites this paper
• Cryopreservation as a Key Element in the Successful Delivery of Cell-Based Therapies—A Review

  2020cites this paper
• Human‐engineered Treg‐like cells suppress FOXP3‐deficient T cells but preserve adaptive immune responses in vivo

  2020influential citation
• A method for expansion and retroviral transduction of mouse regulatory T cells.

  2020cites this paper
• Building a CAR-Treg: Going from the basic to the luxury model.

  2020cites this paper
• [Genetically modified regulatory T cells: therapeutic concepts and regulatory aspects].

  2020cites this paper
• Genetisch modifizierte regulatorische T-Zellen: Therapiekonzepte und ihr regulatorischer Rahmen

  2020influential citation
• CLINICAL-GRADE EXPANDED TREGS ARE ENRICHED WITH HIGHLY SUPPRESSIVE CELLS PRODUCING IL-10, GRANZYME B AND IL-35.

  2020cites this paper
• Metabolic Optimisation of Regulatory T Cells in Transplantation

  2020cites this paper
• Role of the adaptive immune system in atherosclerosis.

  2020cites this paper
• A Comparison of Automated Perfusion- and Manual Diffusion-Based Human Regulatory T Cell Expansion and Functionality Using a Soluble Activator Complex

  2020cites this paper
• Repeated stimulation or tonic-signaling chimeric antigen receptors drive regulatory T cell exhaustion

  2020cites this paper
• Cryopreservation timing is a critical process parameter in a thymic Treg cell therapy manufacturing protocol

  2020cites this paper
• Nanovaccines: An Innovative Technology to Fight Human and Animal Diseases

  2019cites this paper
• Cryopreservation timing is a critical process parameter in a thymic regulatory T-cell therapy manufacturing protocol.

  2019cites this paper
• Regulatory T cells: exploring mechanisms for future therapies

  2019cites this paper
• Perspectives for the Field of Nanovaccines

  2019cites this paper
• CD4+FOXP3+ Regulatory T Cell Therapies in HLA Haploidentical Hematopoietic Transplantation

  2019cites this paper
• Genetic Engineering of T Cells for Immune Tolerance

  2019cites this paper